Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis

Hepato-Gastroenterology

Volumn 56, Issue 93, 2009, Pages 1117-1121

  Mihaila, Romeo Gabriel ^a   Nedelcu, Laurentiu ^b   Fratila, Ovidiu ^c   Rezi, Elena Cristina ^d   Domnariu, Carmen ^e   Deac, Mircea ^a  

^a LUCIAN BLAGA UNIVERSITY OF SIBIU   (Romania)

^b TRANSILVANIA UNIVERSITY OF BRASOV   (Romania)

^c UNIVERSITY OF ORADEA   (Romania)

^d Sibiu Clinical County Hospital   (Romania)

^e Public Health Center   (Romania)

Author keywords

Lovastatin; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Pentoxyphyllin

Indexed keywords

AMINOTRANSFERASE; MEVINOLIN; PENTOXIFYLLINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DRUG EFFICACY; DYSLIPIDEMIA; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; CLINICAL TRIAL; DRUG EFFECT; FATTY LIVER; LIVER FUNCTION TEST; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

DYSLIPIDEMIAS; FATTY LIVER; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER FUNCTION TESTS; LOVASTATIN; MALE; MIDDLE AGED; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; PROSPECTIVE STUDIES; TRANSAMINASES; TREATMENT OUTCOME;

EID: 70350474571     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Charatcharoenwitthaya P, Levy C, Angulo P, Reach J, Jorgensen R, Lindor KD: Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. Liver Int 2007; 27:220-226. (Pubitemid 46680726)
2. Choi S, Diehl AM: Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2005; 21:702-707. (Pubitemid 41578647)
3. Tanaka N, Tanaka E, Sheena Y, Komatsu M, Okiyama W, Misawa N, Muto H, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Horiuchi A, Kiyosawa K: Useful parameters for distinguishing nonalcoholic steatohepatitis with mild steatosis from cryptogenic chronic hepatitis in the Japanese population. Liver Int 2006; 26:956-963. (Pubitemid 44323414)
4. Lennernäs H, Fager G: Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997; 32:403-425. (Pubitemid 27199232)
5. Billups SJ, Plushner SL, Olson KL, Koehler TJ, Kerzee J: Clinical and economic outcomes of conversion of simvastatin to lovastatin in a group-model health maintenance organization. J Manag Care Pharm 2005; 11:681-686.
6. Conforti A, Magro L, Moretti U, Scotto S, Motola D, Salvo F, Ros B, Leone R: Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy. Drug Saf 2006; 29:1163-1172. (Pubitemid 44904831)
7. Vuppalanchi R, Teal E, Chalasani N: Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005; 329:62-65. (Pubitemid 40250595)
8. Cai SR, Motoyama K, Shen KJ, Kennedy SC, Flye MW, Ponder KP: Lovastatin decreases mortality and improves liver functions in fulminant hepatic failure from 90% partial hepatectomy in rats. J Hepatol 2000; 32:67-77. (Pubitemid 30039449)
9. Kiyci M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, Adim SB, Yerci O, Memik F: Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003, 17:713-718. (Pubitemid 38072335)
10. Congdon D: Can patients with steatohepatitis take statins? J Family Practice 2006; 55:10.
11. Browning JD: Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006; 44:466-471.
12. Sochman J: Fatty liver disease and statins - which discipline the problem belongs to? Cas Lek Cesk. 2006; 145:443-446.
13. Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM: Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006; 55:1650-1660. (Pubitemid 44629217)
14. Adams LA, Zein CO, Angulo A, Lindor KD: A pilot trial of Pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004, 99:2365-2368. (Pubitemid 40039367)
15. Sasaki N, Ueno T, Morita Y, Nagata E, Sata M: Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH). Hepatogastroenterology 2006; 53:678-681. (Pubitemid 44682981)